Mastocytosis
33
6
7
18
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
6.1%
2 terminated out of 33 trials
90.0%
+3.5% vs benchmark
0%
0 trials in Phase 3/4
22%
4 of 18 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 18 completed trials
Clinical Trials (33)
Study of Factors Regulating Mast Cell Proliferation
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Pregnancy and Medically Assisted Conception in Rare Diseases
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Institutional Registry of Rare Diseases
Analysis of the Role of IgE Proteoforms in Health and Disease
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
Cromoglicate in Mastocytosis
Myeloproliferative Neoplasms (MPNs) Patient Registry
Mastocytosis Registry (of Zurich)
Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis
Study of Cellular Heterogeneity in Patients With Mastocytosis
Angioedema Biomarker Research Study
Study of Mast Cell Precursors
Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients
Mast Cell Connect: A Registry for Patients With Mastocytosis
Assessment of Burden Disease in Patients With Mast Cell Disorders
Mast Cell Activation Test in Allergic Disease
Cause and Natural Course of Pediatric-Onset Mastocytosis